PALO ALTO, Calif., April 30 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGOE - News), a late stage biotechnology company focused on commercializing its proprietary cellular energy modulation technology, announced today that it has filed a composition of matter patent application with the United States Patent and Trademark Office (USPTO) to cover potential treatments for Huntington’s disease, a fatal neurodegenerative disease.
